108 related articles for article (PubMed ID: 2988280)
1. Serum thymidine kinase as a prognostic marker in Hodgkin's disease.
Eriksson B; Hagberg H; Glimelius B; Sundström C; Gronowitz S; Källander C
Acta Radiol Oncol; 1985; 24(2):167-71. PubMed ID: 2988280
[TBL] [Abstract][Full Text] [Related]
2. Serum levels of interleukin-2 receptor (CD 25) in patients with Hodgkin's disease, with special reference to age and prognosis.
Enblad G; Sundström C; Gronowitz S; Glimelius B
Ann Oncol; 1995 Jan; 6(1):65-70. PubMed ID: 7710984
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of plasma levels of thymidine kinase and mutated p53 in 81 patients with newly diagnosed malignant lymphoma.
Lehtinen T; Aine R; Kellokumpu-Lehtinen P; Hakala T; Lehtinen M
Acta Oncol; 1993; 32(7-8):779-81. PubMed ID: 8305226
[TBL] [Abstract][Full Text] [Related]
4. Serum soluble CD27, but not thymidine kinase, is an independent prognostic factor for outcome in indolent non-Hodgkin's lymphoma.
Kok M; Bonfrer JM; Korse CM; de Jong D; Kersten MJ
Tumour Biol; 2003; 24(1):53-60. PubMed ID: 12743427
[TBL] [Abstract][Full Text] [Related]
5. Biochemical markers in non-Hodgkin's lymphoma stages III and IV and prognosis: a multivariate analysis.
Hagberg H; Glimelius B; Gronowitz S; Killander A; Källander C; Schröder T
Scand J Haematol; 1984 Jul; 33(1):59-67. PubMed ID: 6379852
[TBL] [Abstract][Full Text] [Related]
6. The use of serum deoxythymidine kinase as a prognostic marker, and in the monitoring of patients with non-Hodgkin's lymphoma.
Gronowitz JS; Hagberg H; Källander CF; Simonsson B
Br J Cancer; 1983 Apr; 47(4):487-95. PubMed ID: 6849793
[TBL] [Abstract][Full Text] [Related]
7. [Feasibility study of application of international prognostic score on prediction of prognosis for advanced Hodgkin's lymphoma].
Fu XH; Wang SS; Huang Y; Wang B; Huang HQ; Zhang L; Sun XF; Xu RH; Lin TY
Ai Zheng; 2006 Aug; 25(8):1013-8. PubMed ID: 16965685
[TBL] [Abstract][Full Text] [Related]
8. A comparative study of proliferation-associated parameters in B-cell non-Hodgkin lymphoma.
Rehn S; Glimelius B; Sundström C
Hematol Oncol; 1991; 9(6):287-98. PubMed ID: 1748395
[TBL] [Abstract][Full Text] [Related]
9. Serum beta(2)-microglobulin and serum thymidine kinase are independent predictors of progression-free survival in chronic lymphocytic leukemia and immunocytoma.
Hallek M; Wanders L; Ostwald M; Busch R; Senekowitsch R; Stern S; Schick HD; Kuhn-Hallek I; Emmerich B
Leuk Lymphoma; 1996 Aug; 22(5-6):439-47. PubMed ID: 8882957
[TBL] [Abstract][Full Text] [Related]
10. An in-house assay for serum deoxythymidine kinase.
Seah LH; Ton SH; Cheong SK; Hamidah NH
Malays J Pathol; 1991 Dec; 13(2):109-13. PubMed ID: 1823092
[TBL] [Abstract][Full Text] [Related]
11. [Serum thymidine kinase in multiple myeloma: II. Relation to disease activity and stage].
Scudla V; Papajík T; Bacovský J; Budíková M; Klímová D
Vnitr Lek; 1994 Mar; 40(3):157-62. PubMed ID: 8184567
[TBL] [Abstract][Full Text] [Related]
12. Prognostic relevance of thymidine kinase isozymes in adult non-Hodgkin's lymphoma.
Ellims PH; Eng Gan T; Medley G; Van Der Weyden MB
Blood; 1981 Nov; 58(5):926-30. PubMed ID: 7296003
[TBL] [Abstract][Full Text] [Related]
13. Subdiaphragmatic stage I & II Hodgkin's disease: long-term follow-up and prognostic factors.
Liao Z; Ha CS; Fuller LM; Hagemeister FB; Cabanillas F; Tucker SL; Hess MA; Cox JD
Int J Radiat Oncol Biol Phys; 1998 Jul; 41(5):1047-56. PubMed ID: 9719114
[TBL] [Abstract][Full Text] [Related]
14. Thymidine kinase: a tumor marker with prognostic value for non-Hodgkin's lymphoma and a broad range of potential clinical applications.
Hallek M; Wanders L; Strohmeyer S; Emmerich B
Ann Hematol; 1992 Jul; 65(1):1-5. PubMed ID: 1643153
[TBL] [Abstract][Full Text] [Related]
15. Mantle irradiation alone for pathologic stage I and II Hodgkin's disease: long-term follow-up and patterns of failure.
Liao Z; Ha CS; Vlachaki MT; Hagemeister F; Cabanillas F; Hess M; Tucker S; Cox JD
Int J Radiat Oncol Biol Phys; 2001 Jul; 50(4):971-7. PubMed ID: 11429225
[TBL] [Abstract][Full Text] [Related]
16. Serum thymidine kinase in non-Hodgkin lymphomas with special regard to multiple myeloma.
Poley S; Stieber P; Nüssler V; Pahl H; Fateh-Moghadam A
Anticancer Res; 1997; 17(4B):3025-9. PubMed ID: 9329592
[TBL] [Abstract][Full Text] [Related]
17. Serum thymidine kinase activity: an alternative to histologic markers of cellular proliferation in canine lymphoma.
Madewell BR
J Vet Intern Med; 2004; 18(5):595-6. PubMed ID: 15515571
[TBL] [Abstract][Full Text] [Related]
18. Serum deoxythymidine kinase in small cell carcinoma of the lung. Relation to clinical features, prognosis, and other biochemical markers.
Gronowitz JS; Steinholtz L; Källander CF; Hagberg H; Bergh J
Cancer; 1986 Jul; 58(1):111-8. PubMed ID: 3011236
[TBL] [Abstract][Full Text] [Related]
19. Prognostic relevance of serum thymidine kinase in primary myelodysplastic syndromes: relationship to development of acute myeloid leukaemia.
Musto P; Bodenizza C; Falcone A; D'Arena G; Scalzulli P; Perla G; Modoni S; Parlatore L; Valvano MR; Carotenuto M
Br J Haematol; 1995 May; 90(1):125-30. PubMed ID: 7786774
[TBL] [Abstract][Full Text] [Related]
20. Clinical significance of circulating CD44 in non-Hodgkin's lymphoma.
Ristamäki R; Joensuu H; Hagberg H; Kalkner KM; Jalkanen S
Int J Cancer; 1998 Jun; 79(3):221-5. PubMed ID: 9645341
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
